ytb323,rapcabtagene autoleucel
novartis,novartis
['ytb323', 'lymsm', 'rapcabtagene', 'dlbcl']
congress|#ash22 presented a phase i study update about ytb323 demonstrates durable efficacy &amp; a manageable safety profile in pts with r/r dlbcl was selected as part of the new tools and technologies theme as a best of ash abstract #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm